Close Menu

NEW YORK (GenomeWeb News) – Goldman Sachs on Monday upgraded shares of Danaher's stock, while it downgraded Waters' shares.

Analyst Isaac Ro upgraded Danaher to a Buy rating from a prior rating of Neutral and raised the 12-month price target on the company's stock to $88 from $75. He also downgraded Waters to a Neutral rating from Buy, and reduced the price target on its stock to $107 from $117.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.